SPRY Share Price Performance
US$11.72
1.10 (10.36%)
59.1% undervalued intrinsic discount
US$28.67
Fair Value
Price US$11.72
AnalystConsensusTarget US$28.67
AnalystLowTarget US$12.00
AnalystHighTarget US$40.00
Fair ValueUS$28.67
Share Pricen/a
ARS Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 50 Fair Values set on narratives written by author
SPRY Community Narratives
AN
Fair Value US$28.67 60.3% undervalued intrinsic discount
Worldwide Allergy Trends Will Expand Needle-Free Treatment Access
0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
Fair Value US$12 5.2% undervalued intrinsic discount
Costs And Regulation Will Hinder Prospects But Demand Will Recover
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$40 71.6% undervalued intrinsic discount
Needle-Free Allergy Therapies Will Capture Untapped Global Markets
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Costs And Regulation Will Hinder Prospects But Demand Will Recover
Key Takeaways Heavy reliance on neffy leaves ARS vulnerable to regulatory pressures, payer negotiations, and potential product setbacks impacting future growth and revenue sustainability. Intensifying competition, pricing pressure, and uncertain access to capital threaten margin stability, expansion plans, and investment in long-term pipeline diversification.Read more
27
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$12
5.2% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
33.53% p.a.
Profit Margin
16.03%
Future PE
27.51x
Price in 2028
US$14.83
Worldwide Allergy Trends Will Expand Needle-Free Treatment Access
Key Takeaways Accelerating demand and expanded access for neffy, especially in pediatric and school settings, is driving significant revenue and earnings growth opportunities. Global expansion, new clinical indications, and strong market penetration strategies are broadening revenue streams and creating multiple long-term growth drivers.Read more
214
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
US$28.67
60.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
45.36% p.a.
Profit Margin
9.61%
Future PE
203.69x
Price in 2028
US$35.44
Needle-Free Allergy Therapies Will Capture Untapped Global Markets
Key Takeaways Neffy's needle-free delivery is expanding the allergy treatment market, attracting previously untreated patients and driving greater-than-expected revenue and prescription growth. Enhanced insurance coverage, multi-pack purchasing, and strategic positioning are accelerating recurring sales, expanding margins, and making ARS attractive for global partnerships or acquisition.Read more
35
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$40
71.6% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
75.02% p.a.
Profit Margin
19.17%
Future PE
43.45x
Price in 2028
US$48.29
Trending Discussion
Recently Updated Narratives
AN
SPRY: Neffy Launch Momentum And DTC Campaigns Will Drive Future Upside
Fair Value: US$12 5.2% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SPRY: Needle-Free Delivery Will Capture Market Share From Auto-Injectors
Fair Value: US$28.67 60.3% undervalued intrinsic discount
16 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Needle-Free Allergy Therapies Will Capture Untapped Global Markets
Fair Value: US$40 71.6% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ARS Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.81
- 80.46%
- -56.06%
- 114.0%
About SPRY
- Founded
- 2015
- Employees
- 165
- CEO
- WebsiteView website
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
